Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Other

Merck Patent Gmbh

Klaus Eichmann

Michael D Kramer

Markus M Simon

Ulrich E Schaible

Wallich Reinhard

Manuel Modolell

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of . The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Vaccine against Lyme disease

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies, hybridomas and antigens.

Hybridomas producing antibodies specific for lyme disease antigens OspA

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal anti-bodies and antigens.

Passive vaccine against Lyme disease

A vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Nucleic acid molecule encoding antigen associated with lyme disease

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Growing community of inventors

Freiburg, Germany

Klaus Eichmann